BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.